December 19, 2018

Antibe Therapeutics Raises $1.6 Million Through Warrant Exercises

TORONTO, CANADA — (December 19, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has received gross proceeds of $1.6 million from the exercise of warrants. A total of 7,066,001 warrants were exercised at a price of $0.22 … Continued

read
November 27, 2018

Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

TORONTO, CANADA — (November 27, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the successful completion of part one of the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The study was conducted in 24 … Continued

read
November 23, 2018

Antibe Therapeutics Reports Q2 2019 Interim Financial and Operating Results

TORONTO, CANADA — (November 23, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, November 23rd for the fiscal quarter ended September 30, 2018. The Company’s unaudited fiscal Q2 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR. In addition, the … Continued

read
October 22, 2018

Antibe Therapeutics Establishes Business Development Advisory Board

TORONTO, CANADA — (October 22, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has established a strategic advisory board to support its business development activities. “We are very pleased to welcome four superb pharma executives … Continued

read
October 10, 2018

Antibe Therapeutics Receives Approval to Initiate Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

TORONTO, CANADA — (October 10, 2018) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has received approval from Health Canada to initiate the first part of its Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The first … Continued

read
October 3, 2018

Antibe Therapeutics Announces Grant of Restricted Share Units

TORONTO, CANADA — (October 3, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) announces that it has granted restricted share units (“RSUs”) pursuant to the Company’s RSU plan that was adopted at the most recent annual shareholder’s meeting on June 25, 2018. Walt Macnee, the Chair of Antibe, commented, “The past … Continued

read
September 5, 2018

Antibe Therapeutics Announces Strategic Licensing Deal for Lead Drug in South Korea

License includes C$13 million in non-dilutive milestone payments and a double-digit royalty to Antibe TORONTO, CANADA — (September 5, 2018) – Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has entered into an exclusive licensing agreement with Kwang Dong Pharmaceutical Co., Ltd. (“Kwang … Continued

read
August 29, 2018

Antibe Provides Scientific Report on its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346

TORONTO, CANADA — (August 29, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has prepared a comprehensive report of the recently-completed Phase 2B study for its lead drug, ATB-346. The study was completed in March 2018 … Continued

read

Antibe Therapeutics Reports Q1 2019 Interim Financial and Operating Results

TORONTO, CANADA — (August 29, 2018) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Wednesday, August 29th for the fiscal quarter ended June 30, 2018. The Company’s unaudited fiscal Q1 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR. About Antibe … Continued

read
July 31, 2018

Antibe Therapeutics Provides Clinical Development Update on its Lead Drug

TORONTO, CANADA — (July 31, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to provide an update on its clinical development activities for its lead drug, ATB-346. The Phase 2 dose-ranging, efficacy study remains on track to commence this … Continued

read
July 6, 2018

Antibe Completes Share Issuance in Connection with Citagenix Credit Facility

TORONTO, CANADA — (July 6, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) announces that further to its release of June 29, 2018, it has issued to Bloom Burton Healthcare Lending Trust (“BBHLT”) 578,572 common shares in the capital of Company (“Common Shares”) at a deemed issue price of $0.385 per … Continued

read
July 3, 2018

Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346

TORONTO, CANADA — (July 3, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the secondary endpoint data from the recent Phase 2B gastrointestinal (“GI”) safety study for its lead drug, ATB-346. The double-blind study was conducted in … Continued

read
June 29, 2018

Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results

TORONTO, CANADA — (June 29, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, June 29 for the the fourth quarter and the year ended March 31, 2018. The Company’s audited 2018 consolidated financial statements, MD&A and AIF are available on SEDAR. In addition, … Continued

read
June 26, 2018

Antibe Therapeutics Announces Results of Annual General and Special Meeting

TORONTO, CANADA — (June 26, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual general and special meeting held yesterday. All resolutions proposed to the shareholders were approved, including: The election of directors (Roderick Flower, Amal Khouri, Daniel Legault, Walt Macnee, John Wallace … Continued

read
June 4, 2018

Antibe Therapeutics to Attend 2018 BIO International Convention to Support Partnering Efforts

TORONTO, CANADA — (June 4, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, will be attending the 2018 BIO International Convention (“BIO International”) this week in Boston, Massachusetts. BIO International is the largest biopharma partnering event of the year, attracting over … Continued

read
May 29, 2018

Antibe’s Chief Scientific Officer to Present at 5th World Congress on Hydrogen Sulfide in Biology and Medicine

TORONTO, CANADA — (May 29, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its Chief Scientific Officer, John Wallace, will deliver a lecture at the 5th World Congress on Hydrogen Sulfide in Biology and Medicine. The conference is being held at the Intercontinental Yorkville Hotel in … Continued

read
May 24, 2018

Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology

TORONTO, CANADA — (May 24, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that a team of researchers at the University of Calgary has identified a key mechanism underlying the ability of certain intestinal bacteria to contribute to the ulceration and inflammation that is characteristic of Crohn’s … Continued

read
April 26, 2018

Antibe Therapeutics Announces CEO Letter to Shareholders

TORONTO, ONTARIO – (April 26, 2018) To our stakeholders, The recent success of our lead drug, ATB-346, in its Phase 2B gastrointestinal (“GI”) safety clinical study was a significant milestone for Antibe and represented a major inflection point in our value. Furthermore, we are now one clinical study away from the strategic monetization of our … Continued

read
April 11, 2018

Antibe Therapeutics Engages Blaise Group International for Executive Search

TORONTO, ONTARIO – (April 11, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) has engaged Blaise Group International (“Blaise Group”), a leading healthcare-focused executive recruitment agency, to augment its global business development expertise. Blaise Group is a leading retained human capital search and strategic services firm exclusively servicing life science organizations … Continued

read
April 3, 2018

Antibe Therapeutics Provides Financial Update

TORONTO, ONTARIO – (April 3, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation that recently announced a successful Phase 2B clinical trial demonstrating the gastrointestinal safety of its lead drug, reports that the Company now has a significantly augmented balance sheet. … Continued

read
March 20, 2018

Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Safety Study for Lead Pain Drug, ATB-346

TORONTO, ONTARIO – (March 20, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal (“GI”) safety study. The double-blind study was conducted in 244 healthy volunteers and was designed to demonstrate the superiority of … Continued

read
March 13, 2018

Antibe Therapeutics Announces No Material Change

TORONTO, ONTARIO – (March 13, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) wishes to advise that it is not aware of any undisclosed material change in the Company’s activities that would account for recent market activity. As previously disclosed in its February 26th, 2018 press release, the Company anticipates being … Continued

read
February 27, 2018

Antibe Therapeutics Reports Q3 2018 Interim Financial and Operating Results

TORONTO, CANADA — (February 27, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, February 27th for the fiscal quarter ended December 31, 2017. The Company’s unaudited fiscal Q3 2018 condensed interim consolidated financial statements and MD&A are available on SEDAR. In addition, the … Continued

read
February 26, 2018

Antibe Therapeutics Provides Update on Phase 2B Gastrointestinal Safety Study of Lead Pain Drug, ATB-346

TORONTO, ONTARIO – (February 26, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) would like to confirm the previously announced timing for its Phase 2B double-blind clinical trial of ATB-346. The final subject has now completed treatment and the subsequent two-week monitoring period. The CRO conducting the study, Topstone Research … Continued

read
January 29, 2018

Antibe Therapeutics Announces Enrollment of Final Subjects in Phase 2B Gastrointestinal Safety Study of Lead Pain Drug, ATB-346

TORONTO, CANADA — (January 29, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a diversified biotechnology company with two best-in-class divisions in pain/inflammation and regenerative medicine, is pleased to announce that the final subjects have been enrolled and are on treatment in the key Phase 2B double-blind clinical trial of ATB-346. … Continued

read
January 17, 2018

Antibe Therapeutics Engages Brand Institute to Advise on Nonproprietary Name for ATB-346

TORONTO, ONTARIO – (January 17, 2018) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that it has engaged Brand Institute, Inc. (“Brand Institute”) to advise on the nonproprietary name for its lead drug candidate, ATB-346. Every approved pharmaceutical drug is required to establish an unambiguous international name that … Continued

read

archives